Abstract
TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow
at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors
contributing to this market growth is the increasing prevalence of ovarian
cancer. The Global Ovarian Cancer Drugs market has also been witnessing the
trend of the use of combination therapies for the treatment of ovarian cancer.
However, patent expiration of key drugs could pose a challenge to the growth
of this market.
TechNavio's report, the Global Ovarian Cancer Drugs Market 2011-2015, has been
prepared based on an in-depth analysis of the market with inputs from industry
experts. The report covers the Americas, and the EMEA and APAC regions; it
also covers the market landscape and its growth prospects in the coming years.
The report also includes a discussion of the key vendors operating in this
market.
Key vendors dominating this market space include Eli Lilly and Co.,
GlaxoSmithKline plc, Bristol Myers Squibb Co., and Roche Pharmaceuticals.
Other vendors mentioned in the report are Johnson & Johnson, Amgen Inc., Eisai
Co. Ltd., BioNumerik Pharmaceuticals Inc., Endocyte Inc., Oasmia
Pharmaceutical AB, Boehringer Ingelheim GmbH, and AstraZeneca plc.
Key questions answered in this report:
- What will the market size be in 2015 and at what rate will it grow?
- What key trends is this market subject to?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the opportunities and threats faced by each of these key vendors?
- What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report.
Details provided within the report.
Table of Contents
01. Executive Summary
02. Introduction
03. Market Coverage
- Market Overview
- Product Offerings
04. Market Landscape
- Market Size
- Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
- Economic Indicators of Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
- Major Vendors of the Global Cancer Drugs market
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
- 15.1. Eli Lilly and Co.
- Business Overview
- SWOT Analysis
- 15.2. GlaxoSmithKline plc
- Business Overview
- SWOT Analysis
- 15.3. Bristol-Myers Squibb Co.
- Business Overview
- SWOT Analysis
- 15.4. Roche Pharmaceuticals
- Business Overview
- SWOT Analysis
16. Other Reports in this Series
List of Exhibits:
- Exhibit 1: Global Ovarian Cancer Drugs Market 2011-2015 (US$ million)
- Exhibit 2: Global Ovarian Cancer Drugs Market by Geographical Segmentation
2011
- Exhibit 3: Global Cancer Drugs Market by Vendor Segmentation 2011
Global Ovarian Cancer Drugs Market 2011-2015 published by Infiniti Research Limited (Technavio) in August 27, 2012. This report consists of Pages: 36 and the price starts from US $ 1500.
